▎图表详细信息 返回上一页 >>
Figure 1.
图片来源:

Serum levels of CXCL13 are associated with ultrasonographic synovitis and predict power Doppler persistence in early rheumatoid arthritis treated with non-biological disease-modifying anti-rheumatic drugs,Arthritis Research & Therapy

作者: Roberto Caporali, Carlomaurizio Montecucco, Garifallia Sakellariou, Monica Todoerti, Barbara Vitolo, Catherine Klersy, Francesca Benaglio, Antonio Manzo, Serena Bugatti

图片介绍: Figure 1. Clinical and ultrasonographic outcomes over time according to baseline CXCL13 levels. Baseline CXCL13 levels and progressive achievement of clinical and ultrasonographic (US) outcomes in patients with recent-onset rheumatoid arthritis treated within a structured treat-to-target protocol aiming at low disease activity. Patients were divided into tertiles based on CXCL13 levels. The proportion of patients achieving low disease activity (DAS < 2.4) (A) and a power Doppler score ≤ 1 at ultrasonography (B) at each time point for different CXCL13 thresholds is shown. The mean ± SD CXCL13 levels were 163.6 ± 63.27 pg/ml for the third tertile (lowest value 99.83 pg/ml), 73.57 ± 12.08 pg/ml for the second tertile and 38.44 ± 10.42 pg/ml for the first tertile. Due to the lack of significant differences between the first and the second CXCL13 tertile, clinical and US outcomes are presented together against the third tertile. Values are the mean ± SD.